Purpose: To evaluate the antitumor activity and safety of irinotecan plus cisplatin combination chemotherapy with concurrent thoracic radiotherapy (TRT) in patients with limited disease (LD) small cell lung cancer (SCLC). 
INTRODUCTION
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers (1) , and is almost entirely attributable to cigarette smoking (2) . SCLC is the most aggressive of all the lung cancer cell types. SCLC has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastasis compared to non-small cell lung cancer (NSCLC). Only one-third of patients diagnosed with SCLC present with limited disease (LD).
As new chemotherapy regimens were developed in the mid-1970s, the median overall survival (OS) of patients with LD SCLC increased from 6 to 18 months, and the OS of patients with extensive disease (ED) reached 9 months. Disappointingly, there has been almost no progress in the survivorship of SCLC since the mid-1980s (3).
Irinotecan, a topoisomerase I inhibitor, has raised significant interest as an alternative to etoposide, the standard agent of SCLC, when used in combination with platinum-based agents (4) (5) (6) . A Japanese phase III trial (7) reported that patients with ED SCLC who were treated with irinotecan plus cisplatin had a median OS of 12.8 months, whereas those treated with etoposide plus cisplatin achieved an OS of only 9.4 months (p=0.002). However, two other phase III trials performed in the United States failed to reproduce the superiority of irinotecan in patients with ED SCLC (8, 9) . Nevertheless, irinotecan is now considered an available option of chemotherapy for patients with ED SCLC (10) .
For patients with LD SCLC, etoposide plus cisplatin with concurrent thoracic radiotherapy (TRT) is regarded as standard first-line treatment. TRT was introduced for the treatment of LD SCLC in the 1980s in an effort to achieve improved local control rate and fewer relapses at the primary site. As two meta-analyses demonstrated a survival advantage of approximately 4% at 2 years (11, 12) , TRT became an essential component of treatment for patients with LD SCLC.
The aim of this study was to evaluate the safety profile and antitumor activity of combination chemotherapy of irinotecan and cisplatin with concurrent TRT in patients with LD SCLC.
MATERIALS AND METHODS

1) Patients
The data of patients with LD SCLC treated with combination After the completion of each cycle, a safety evaluation, including an assessment of laboratory data and any clinical 
4) Statistical analysis
The primary endpoint of this study was to evaluate both the toxicity and response rate of combination chemotherapy concurrent with TRT in the patients with LD SCLC. Progression-free survival (PFS) and overall survival (OS) were measured as a secondary endpoint. All eligible patients who received at least 1 cycle of chemotherapy were included for survival estimation and toxicity evaluation. PFS was defined as the time from commencement of treatment until disease progression or death. OS was calculated from the first time of treatment to death from any cause. We additionally measured time to progression (TTP), in which the deaths of patients from other than progression were censored compared to PFS.
PFS and OS were calculated using the Kaplan-Meier method.
All statistical analyses were performed with the SPSS software version 15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
1) Patient characteristics
Nineteen patients (median age, 58 years; age range, 47∼74 years) received combination chemotherapy concurrent with TRT. Seventeen patients were male and most of the patients were smokers. The detailed patient characteristics are sum- 
2) Treatment outcomes
All of the 19 patients were evaluable for tumor response; the best overall response was a CR in 8 (42.1%), partial response 
3) Toxicity profile
The recorded adverse events are summarized in Table 2 .
Hematologic toxicities were modest and there was no grade 4 hematologic toxicity or episodes of neutropenic fevers during the treatment. The frequently reported toxicities were nausea (10 patients, 53%), radiation-induced pneumonitis (10 patients, 53%), and neutropenia (6 patients, 32%). The frequently reported severe toxicities (i.e., grades, 3∼5) were stomatitis (5 patients, 26%), nausea (4 patients, 21%), and esophagitis (4 patients, 21%). Three patients died during the treatment and were considered treatment-related deaths; two patients died of fatal pneumonia (fungal pneumonia and pneumococcal pneumonia) without neutropenia and the other patient probably died of severe radiation-induced pneumonitis, as there was no growth report on his blood, sputum, and bronchoscopic lavage culture, and the pulmonary lesion was located in the radiation field.
4) Pattern of treatment failure
Excluding 3 patients with treatment related mortality and 4 patients who maintained CR after the treatment, 12 patients had either documented relapse after CR or progression of SCLC:
there was 1 patient with locoregional failure alone, 10 patients with distant metastasis alone, and 1 patient experienced both locoregional and distant failures. The common sites of distant metastases were as follows: liver, 3 patients; brain, 3 patients; bone, 2 patients; distant lymph nodes, 2 patients; and lung other than the primary lesion, 1 patient (a patient may have had ＞2
sites of distant metastases).
DISCUSSION
As irinotecan plus cisplatin combination chemotherapy has been shown to be at least comparable to the standard etoposide plus cisplatin regimen in patients with ED SCLC, introduction of irinotecan for the treatment of patients with LD SCLC is a rational approach. In the current study, we achieved a high response rate and survival, which were similar to historic data of concurrent chemoradiation in patients with LD SCLC. Although neutropenia was one of the most common reported toxicities, most of the patients recovered without significant infections and there was no grade 4 neutropenia. In contrast, this study showed a significant incidence of TRT-related complications. As we left the decision regarding additional TRT after 54 Gy to the radiologic oncologists, higher doses of radiation were administered to most patients (median, 59.4 Gy).
It appears that high doses of irradiation may have a relationship to adverse events, despite of the fact that high doses of irradiation might contribute to improved locoregional control.
Thus, one patient died of severe radiation-induced pneumonitis, and in the other 2 patients who died of severe pneumonia, combined pre-existing radiation pneumonitis (one with grade 1 and the other with grade 2) probably limited their lung function.
CONCLUSION
Although the current study was a retrospective analysis with a limited number of patients, a significant tumor response was demonstrated, which was the primary endpoint of the analysis.
Introduction of irinotecan in combination with platinum in patients with LD SCLC was effective and tolerable. Further prospective phase III clinical trial is warranted.
